Tazeen Ahmad
Stock Analyst at B of A Securities
(3.46)
# 938
Out of 5,127 analysts
213
Total ratings
48.1%
Success rate
4.68%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Upgrades: Buy | $627 → $860 | $816.00 | +5.39% | 1 | Jan 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $72 → $58 | $23.86 | +143.08% | 7 | Jan 2, 2026 | |
| FULC Fulcrum Therapeutics | Maintains: Underperform | $6 → $7 | $10.31 | -32.10% | 7 | Dec 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $71 → $112 | $76.58 | +46.25% | 1 | Dec 9, 2025 | |
| PHVS Pharvaris | Maintains: Neutral | $27 → $30 | $24.58 | +22.05% | 5 | Dec 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $26 → $29 | $26.16 | +10.86% | 9 | Oct 20, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $53 | $42.35 | +25.15% | 1 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $453 → $520 | $414.38 | +25.49% | 5 | Sep 17, 2025 | |
| INCY Incyte | Maintains: Buy | $90 → $104 | $106.18 | -2.05% | 6 | Sep 4, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $227 → $230 | $211.64 | +8.68% | 11 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $880 → $887 | $812.85 | +9.12% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $16 | $23.55 | -32.06% | 26 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $76 | $76.15 | -0.20% | 19 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $27 | $26.81 | +0.71% | 16 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $99.55 | +34.61% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $5.18 | +54.44% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $98.05 | -3.11% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.71 | +94.55% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $9.08 | -55.95% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $11.27 | -29.02% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $17.17 | +57.25% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $12.30 | +127.64% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $7.31 | +447.20% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $137.02 | +30.64% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $16.27 | +35.22% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $7.00 | -57.14% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.29 | +5.01% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $5.41 | +84.84% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.06 | +466.04% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $11.70 | +28.26% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.57 | -43.98% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $2.79 | +115.05% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $19.54 | -23.23% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $300.13 | -80.01% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.42 | +1,026.76% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $172.86 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $17.36 | +1,628.61% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.54 | +255.03% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $26.22 | +83.10% | 6 | Oct 10, 2018 |
Regeneron Pharmaceuticals
Jan 7, 2026
Upgrades: Buy
Price Target: $627 → $860
Current: $816.00
Upside: +5.39%
Ultragenyx Pharmaceutical
Jan 2, 2026
Maintains: Buy
Price Target: $72 → $58
Current: $23.86
Upside: +143.08%
Fulcrum Therapeutics
Dec 9, 2025
Maintains: Underperform
Price Target: $6 → $7
Current: $10.31
Upside: -32.10%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $71 → $112
Current: $76.58
Upside: +46.25%
Pharvaris
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $24.58
Upside: +22.05%
Apellis Pharmaceuticals
Oct 20, 2025
Maintains: Neutral
Price Target: $26 → $29
Current: $26.16
Upside: +10.86%
Scholar Rock Holding
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $42.35
Upside: +25.15%
Alnylam Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $453 → $520
Current: $414.38
Upside: +25.49%
Incyte
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $106.18
Upside: -2.05%
Ascendis Pharma
Sep 2, 2025
Maintains: Buy
Price Target: $227 → $230
Current: $211.64
Upside: +8.68%
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $812.85
Upside: +9.12%
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $23.55
Upside: -32.06%
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $76.15
Upside: -0.20%
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $26.81
Upside: +0.71%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $99.55
Upside: +34.61%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $5.18
Upside: +54.44%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $98.05
Upside: -3.11%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $7.71
Upside: +94.55%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $9.08
Upside: -55.95%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $11.27
Upside: -29.02%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $17.17
Upside: +57.25%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $12.30
Upside: +127.64%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $7.31
Upside: +447.20%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $137.02
Upside: +30.64%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $16.27
Upside: +35.22%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $7.00
Upside: -57.14%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.29
Upside: +5.01%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $5.41
Upside: +84.84%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.06
Upside: +466.04%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $11.70
Upside: +28.26%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.57
Upside: -43.98%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $2.79
Upside: +115.05%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $19.54
Upside: -23.23%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $300.13
Upside: -80.01%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.42
Upside: +1,026.76%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $172.86
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $17.36
Upside: +1,628.61%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.54
Upside: +255.03%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $26.22
Upside: +83.10%